Latest close: $16.25 (Feb 14, 2025)
Regular market change: -2.29%
Post-market movement: +1.05%
Current trading range: Support at $15.86, Resistance at $17.53 (Fibonacci levels)

Fundamental Catalysts

Recent settlement agreement with Axsome Therapeutics regarding Auvelity patent litigation
Increased institutional interest as Druckenmiller's Duquesne Family Office increased its position in TEVA, making it their fourth-largest holding
Filed mixed securities shelf offering recently

Recommendation Given the current technical weakness but positive fundamental developments, it would be prudent to HOLD TEVA stock at current levels. While the stock appears oversold technically, suggesting a potential bounce, the mixed shelf offering announcement could create near-term selling pressure. Consider entering new positions if the stock stabilizes above the Fibonacci support level of $15.86.

What is price prediction 2025 for TEVA Stock?

Based on the provided data and recent market events, here's a detailed price prediction analysis for TEVA stock in 2025:

Current Market Position

Technical Analysis

Current price: $16.42 (as of Feb 14, 2025)
Major support levels: $15.86, $15.22 (Fibonacci)
Major resistance levels: $17.53, $17.92 (Fibonacci)
RSI-14 at 26.69 indicates oversold conditions
MACD showing bearish momentum with -1.13 value

Recent Events Impact

Q4 2024 earnings released on January 29, 2025, triggered a significant selloff
Stock dropped ~13% after providing lower-than-expected 2025 guidance
2025 EPS guidance of $2.35-$2.65 fell below consensus of $2.78

Price Target Scenarios

Bullish Case ($19-20):

Probability: 35%
Drivers: Strong execution of Pivot to Growth strategy and better-than-expected performance of key products like Austedo and Uzedy
Technical recovery from current oversold conditions

Base Case ($16-18):

Probability: 45%
Drivers: In-line execution with current guidance
Consolidation around current levels with gradual recovery

Bearish Case ($14-15):

Probability: 20%
Drivers: Further margin pressure or execution challenges
Break below key support levels

Most Likely Scenario The base case appears most probable, with a target range of $16-18 by end of 2025, supported by:

Management's conservative guidance
Continued growth in key products like Austedo
Technical indicators suggesting potential bottoming process

What is surpport and resistant level for TEVA Stock?

The S1 support level for TEVA Stock is $16.21 ,The R1 resistant level for TEVA Stock is $17.39.

What is the current price of TEVA Stock?

As of the end of day on 2025-02-21, the price of TEVA Stock was $16.703.

What is the target price of TEVA Stock?

The target price for TEVA Stock according to analyst rating is 24.50, with the highest price target at 30.00 and the lowest at 20.00. Analysts have a Strong Buy rating on TEVA Stock overall.

What is the market cap of Teva Pharmaceutical Industries Ltd?

The market cap of TEVA is $19.2B.

Is Teva Pharmaceutical Industries Ltd (TEVA) overvalued?

Based on the provided data and recent market developments, here's a concise analysis of TEVA's valuation:

TEVA appears fairly valued at current levels considering its recent financial performance and market position. The company's EV/EBITDA ratio of 6.16 for FY2023 indicates reasonable valuation compared to industry peers. The significant improvement in net loss from -$2.4B in 2022 to -$559M in 2023 shows operational progress. However, the recent guidance miss for 2025 earnings ($2.35-$2.65 vs consensus $2.78) has created downward pressure on the stock.

The company's price-to-sales ratio of 0.74 and price-to-book ratio of 1.56 suggest moderate valuation levels, while technical indicators show the stock is currently oversold with RSI-14 at 26.69. The stock's recent decline of 12.5% following earnings guidance has brought it closer to fair value territory.

The current market positioning near key Fibonacci support levels (S1: $16.25) suggests limited downside risk at these price levels, though near-term volatility may persist due to the recent guidance disappointment.

What is Teva Pharmaceutical Industries Ltd (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is price prediction 2030 for TEVA Stock?

Based on the available data and market analysis, here is the price prediction for TEVA stock by 2030:

TEVA stock is projected to reach $32-35 by 2030, representing a ~100% upside from current levels, driven by successful execution of its "Pivot to Growth" strategy and expansion in biosimilars and specialty medicines. The company's positive Phase 2b results for duvakitug and partnership with Sanofi provide strong growth catalysts. However, recent guidance miss and margin pressure suggest the growth trajectory may be volatile.

The technical analysis shows TEVA is currently in a consolidation phase after a significant decline following its 2025 guidance miss in January. The stock needs to break above key resistance at $17.53 (Fibonacci R1) to confirm upward momentum.